Selected research
Industry Research
Hepatitis A immunoglobulin Industry Research Report 2026
Market perspective
The global Hepatitis A immunoglobulin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Hepatitis A immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Hepatitis A immunoglobulin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Hepatitis A immunoglobulin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Hepatitis A immunoglobulin include CSL Behring, Dr. Reddy's Laboratories, Native Antigen, AIM Vaccine, GSK, Sinovac Biotech, Merck, Pukang Biotechnology and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Hepatitis A immunoglobulin market in terms of revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hepatitis A immunoglobulin Market by Company
CSL Behring
Dr. Reddy's Laboratories
Native Antigen
AIM Vaccine
GSK
Sinovac Biotech
Merck
Pukang Biotechnology
Sanofi
Changchun Lnstitute Of Biological Products
Zhifei Biological Products
Hepatitis A immunoglobulin Segment by Type
Inactivated
Attenuated
Hepatitis A immunoglobulin Segment by Application
Hospital
Pharmacy
Other
Hepatitis A immunoglobulin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis A immunoglobulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatitis A immunoglobulin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis A immunoglobulin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Hepatitis A immunoglobulin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Hepatitis A immunoglobulin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Hepatitis A immunoglobulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Inactivated
- Attenuated
Applications
- Hospital
- Pharmacy
- Other
Companies covered
- CSL Behring
- Dr. Reddy's Laboratories
- Native Antigen
- AIM Vaccine
- GSK
- Sinovac Biotech
- Merck
- Pukang Biotechnology
- Sanofi
- Changchun Lnstitute Of Biological Products
- Zhifei Biological Products
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Hepatitis A immunoglobulin Market Size (2021-2032)
- 2.2.2 Global Hepatitis A immunoglobulin Sales (2021-2032)
- 2.2.3 Global Hepatitis A immunoglobulin Market Average Price (2021-2032)
- 2.3 Hepatitis A immunoglobulin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Inactivated
- 2.3.3 Attenuated
- 2.4 Hepatitis A immunoglobulin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Pharmacy
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Hepatitis A immunoglobulin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Hepatitis A immunoglobulin Sales (Units) of Manufacturers (2021-2026)
- 3.3 Global Hepatitis A immunoglobulin Revenue of Manufacturers (2021-2026)
- 3.4 Global Hepatitis A immunoglobulin Average Price by Manufacturers (2021-2026)
- 3.5 Global Hepatitis A immunoglobulin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Hepatitis A immunoglobulin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Hepatitis A immunoglobulin, Product Type & Application
- 3.8 Global Manufacturers of Hepatitis A immunoglobulin, Established Date
- 3.9 Global Hepatitis A immunoglobulin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CSL Behring
- 4.1.1 CSL Behring Company Information
- 4.1.2 CSL Behring Business Overview
- 4.1.3 CSL Behring Hepatitis A immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CSL Behring Hepatitis A immunoglobulin Product Portfolio
- 4.1.5 CSL Behring Recent Developments
- 4.2 Dr. Reddy's Laboratories
- 4.2.1 Dr. Reddy's Laboratories Company Information
- 4.2.2 Dr. Reddy's Laboratories Business Overview
- 4.2.3 Dr. Reddy's Laboratories Hepatitis A immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Dr. Reddy's Laboratories Hepatitis A immunoglobulin Product Portfolio
- 4.2.5 Dr. Reddy's Laboratories Recent Developments
- 4.3 Native Antigen
- 4.3.1 Native Antigen Company Information
- 4.3.2 Native Antigen Business Overview
- 4.3.3 Native Antigen Hepatitis A immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Native Antigen Hepatitis A immunoglobulin Product Portfolio
- 4.3.5 Native Antigen Recent Developments
- 4.4 AIM Vaccine
- 4.4.1 AIM Vaccine Company Information
- 4.4.2 AIM Vaccine Business Overview
- 4.4.3 AIM Vaccine Hepatitis A immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AIM Vaccine Hepatitis A immunoglobulin Product Portfolio
- 4.4.5 AIM Vaccine Recent Developments
- 4.5 GSK
- 4.5.1 GSK Company Information
- 4.5.2 GSK Business Overview
- 4.5.3 GSK Hepatitis A immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GSK Hepatitis A immunoglobulin Product Portfolio
- 4.5.5 GSK Recent Developments
- 4.6 Sinovac Biotech
- 4.6.1 Sinovac Biotech Company Information
- 4.6.2 Sinovac Biotech Business Overview
- 4.6.3 Sinovac Biotech Hepatitis A immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sinovac Biotech Hepatitis A immunoglobulin Product Portfolio
- 4.6.5 Sinovac Biotech Recent Developments
- 4.7 Merck
- 4.7.1 Merck Company Information
- 4.7.2 Merck Business Overview
- 4.7.3 Merck Hepatitis A immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Merck Hepatitis A immunoglobulin Product Portfolio
- 4.7.5 Merck Recent Developments
- 4.8 Pukang Biotechnology
- 4.8.1 Pukang Biotechnology Company Information
- 4.8.2 Pukang Biotechnology Business Overview
- 4.8.3 Pukang Biotechnology Hepatitis A immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pukang Biotechnology Hepatitis A immunoglobulin Product Portfolio
- 4.8.5 Pukang Biotechnology Recent Developments
- 4.9 Sanofi
- 4.9.1 Sanofi Company Information
- 4.9.2 Sanofi Business Overview
- 4.9.3 Sanofi Hepatitis A immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Sanofi Hepatitis A immunoglobulin Product Portfolio
- 4.9.5 Sanofi Recent Developments
- 4.10 Changchun Lnstitute Of Biological Products
- 4.10.1 Changchun Lnstitute Of Biological Products Company Information
- 4.10.2 Changchun Lnstitute Of Biological Products Business Overview
- 4.10.3 Changchun Lnstitute Of Biological Products Hepatitis A immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Changchun Lnstitute Of Biological Products Hepatitis A immunoglobulin Product Portfolio
- 4.10.5 Changchun Lnstitute Of Biological Products Recent Developments
- 4.11 Zhifei Biological Products
- 4.11.1 Zhifei Biological Products Company Information
- 4.11.2 Zhifei Biological Products Business Overview
- 4.11.3 Zhifei Biological Products Hepatitis A immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Zhifei Biological Products Hepatitis A immunoglobulin Product Portfolio
- 4.11.5 Zhifei Biological Products Recent Developments
5 Global Hepatitis A immunoglobulin Market Scenario by Region
- 5.1 Global Hepatitis A immunoglobulin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Hepatitis A immunoglobulin Sales by Region: 2021-2032
- 5.2.1 Global Hepatitis A immunoglobulin Sales by Region: 2021-2026
- 5.2.2 Global Hepatitis A immunoglobulin Sales by Region: 2027-2032
- 5.3 Global Hepatitis A immunoglobulin Revenue by Region: 2021-2032
- 5.3.1 Global Hepatitis A immunoglobulin Revenue by Region: 2021-2026
- 5.3.2 Global Hepatitis A immunoglobulin Revenue by Region: 2027-2032
- 5.4 North America Hepatitis A immunoglobulin Market Facts & Figures by Country
- 5.4.1 North America Hepatitis A immunoglobulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Hepatitis A immunoglobulin Sales by Country (2021-2032)
- 5.4.3 North America Hepatitis A immunoglobulin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Hepatitis A immunoglobulin Market Facts & Figures by Country
- 5.5.1 Europe Hepatitis A immunoglobulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Hepatitis A immunoglobulin Sales by Country (2021-2032)
- 5.5.3 Europe Hepatitis A immunoglobulin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Hepatitis A immunoglobulin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Hepatitis A immunoglobulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Hepatitis A immunoglobulin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Hepatitis A immunoglobulin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Hepatitis A immunoglobulin Market Facts & Figures by Country
- 5.7.1 South America Hepatitis A immunoglobulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Hepatitis A immunoglobulin Sales by Country (2021-2032)
- 5.7.3 South America Hepatitis A immunoglobulin Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Hepatitis A immunoglobulin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Hepatitis A immunoglobulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Hepatitis A immunoglobulin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Hepatitis A immunoglobulin Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Hepatitis A immunoglobulin Sales by Type (2021-2032)
- 6.1.1 Global Hepatitis A immunoglobulin Sales by Type (2021-2032) & (Units)
- 6.1.2 Global Hepatitis A immunoglobulin Sales Market Share by Type (2021-2032)
- 6.2 Global Hepatitis A immunoglobulin Revenue by Type (2021-2032)
- 6.2.1 Global Hepatitis A immunoglobulin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Hepatitis A immunoglobulin Revenue Market Share by Type (2021-2032)
- 6.3 Global Hepatitis A immunoglobulin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Hepatitis A immunoglobulin Sales by Application (2021-2032)
- 7.1.1 Global Hepatitis A immunoglobulin Sales by Application (2021-2032) & (Units)
- 7.1.2 Global Hepatitis A immunoglobulin Sales Market Share by Application (2021-2032)
- 7.2 Global Hepatitis A immunoglobulin Revenue by Application (2021-2032)
- 7.2.1 Global Hepatitis A immunoglobulin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Hepatitis A immunoglobulin Revenue Market Share by Application (2021-2032)
- 7.3 Global Hepatitis A immunoglobulin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Hepatitis A immunoglobulin Value Chain Analysis
- 8.1.1 Hepatitis A immunoglobulin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Hepatitis A immunoglobulin Production Mode & Process
- 8.2 Hepatitis A immunoglobulin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Hepatitis A immunoglobulin Distributors
- 8.2.3 Hepatitis A immunoglobulin Customers
9 Global Hepatitis A immunoglobulin Analyzing Market Dynamics
- 9.1 Hepatitis A immunoglobulin Industry Trends
- 9.2 Hepatitis A immunoglobulin Industry Drivers
- 9.3 Hepatitis A immunoglobulin Industry Opportunities and Challenges
- 9.4 Hepatitis A immunoglobulin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst